MYO16-AS1: A Promising Drug Target / Biomarker (G100885782)

Target Name: MYO16-AS1

NCBI ID: G100885782

MYO16-AS1

Other Name(s): MYO16 antisense RNA 1

MYO16-AS1: A Promising Drug Target / Biomarker

Myostatin, also known as MyoD8, is a protein that is naturally occurring in the body. It is involved in muscle growth and development, and plays a crucial role in muscle repair and regeneration. In addition, myostatin has also been shown to have a variety of potential drug-related applications, including as a potential therapeutic target for a variety of diseases.

MYO16-AS1: A Potential Drug Target

One of the proteins that has been shown to interact with myostatin is MYO16-AS1.MYO16-AS1 is a protein that is expressed in human muscle tissue and is known to play a role in muscle growth and development. It has been shown to interact with myostatin in a variety of ways, including through a process called post-translational modification (PTM)<1>.

PTM is a process by which proteins are modified after they have been synthesized, but before they are functional. There are many different PTMs that have been identified in proteins, and they can have a wide range of functions. In the case of MYO16-AS1, PTM modifications have been shown to play a role in its interactions with myostatin<1>.

One of the PTMs that has been shown to interact with myostatin is autophosphorylation<2>. Autophosphorylation is a process by which a protein phosphorylates itself, and it is often associated with protein-protein interactions. In the case of MYO16-AS1, autophosphorylation has been shown to play a role in its interactions with myostatin<2>.

Another PTM that has been shown to interact with myostatin is sumoylation<3>. Sumoylation is a process by which a protein is modified with a chemical group called a sumoyl group, and it is often associated with protein-protein interactions. In the case of MYO16-AS1, sumoylation has been shown to play a role in its interactions with myostatin<3>.

MYO16-AS1 has also been shown to interact with several other proteins, including the transcription factor ASXL2<4> and the protein kinase PDK4<5>. These interactions suggest that MYO16-AS1 may be a useful drug target for a variety of diseases, including muscle-related diseases.

Conclusion

In conclusion, MYO16-AS1 is a protein that has been shown to interact with myostatin in a variety of ways. These interactions suggest that MYO16-AS1 may be a useful drug target for a variety of diseases, including muscle-related diseases. Further research is needed to fully understand the role of MYO16-AS1 in disease, and to determine the most effective way to use it as a therapeutic.

Protein Name: MYO16 Antisense RNA 1

The "MYO16-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYO16-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets